Herein, we describe the exploration of 3 biomarkers—human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24—as potential radiotheranostic targets for endometrial cancer. The gene discussed is CD24; the disease is endometrial cancer.